{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T04:12:52Z","timestamp":1749010372950,"version":"3.41.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","funder":[{"DOI":"10.13039\/100007365","name":"Fondazione IRCCS Policlinico San Matteo","doi-asserted-by":"crossref","award":["0003465\/22"],"award-info":[{"award-number":["0003465\/22"]}],"id":[{"id":"10.13039\/100007365","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Busulfan (Bu), an alkylating agent commonly used in chemotherapy and transplantation, exhibits high intraindividual pharmacokinetic variability and possible time-dependent variations in clearance, which complicate therapeutic drug monitoring. Numerous analytical methods have been developed to reduce analysis time and facilitate timely decision-making regarding treatment changes; however, the validation procedures rarely involve analysis of potentially interfering excipients. Macrogol 400 (PEG 400) should be considered as a possible interfering agent in the detection of plasma Bu levels, especially as an ionization suppressor.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Six intravenous formulations of Bu were compared with identify at least 1 common excipient (PEG 400). During the 176 therapeutic drug monitoring analyses of Bu, one of the PEG 400 specific mass-to-charge ratio transitions was determined using an instrumental method. After coelution with Bu and its internal standard (Bu-d8) was confirmed, all analyses were repeated using a different experimental setup free of ion suppression induced by PEG. The concentration\u2013time profile of PEG 400 was also analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The area under the curve obtained from the 2 data sets was compared and analyzed using Lin concordance correlation coefficient and Bland\u2013Altman plot analysis. The results from the 2 analytical methods were comparable: PEG 400 negatively affected the Bu-d8 coefficient of variation but not the Bu\/Bu-d8 ratio.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The possible interference of PEG 400 should be thoroughly investigated, especially with respect to analytical methods that cannot be supported by correction of the stable isotopically labeled internal standard analog.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001130","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T04:01:22Z","timestamp":1694232082000},"page":"827-831","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["PEG 400 Ion Suppression in Busulfan Detection by High-Performance Liquid Chromatography\u2014Tandem Mass Spectrometry"],"prefix":"10.1097","volume":"45","author":[{"given":"Simona","family":"De Gregori","sequence":"first","affiliation":[{"name":"Clinical and Experimental Pharmacokinetics Unit, Department of Diagnostic Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara","family":"Capone","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Pharmacokinetics Unit, Department of Diagnostic Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"De Silvestri","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology and Biometry Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Albertini","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Pharmacokinetics Unit, Department of Diagnostic Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jtct.2022.01.013","article-title":"Association between the magnitude of intravenous Busulfan exposure and development of hepatic veno-occlusive disease in children and young adults undergoing myeloablative allogeneic hematopoietic cell transplantation","volume":"28","author":"Bogn\u00e0r","year":"2022","journal-title":"Transplant Cell Ther."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jtct.2022.03.001","article-title":"VOD\/SOS and Alkylating agents in the hematopoietic stem cell transplant setting: new insights and further questions","volume":"28","author":"Myers","year":"2022","journal-title":"Transplant Cell Ther."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bbmt.2007.09.015","article-title":"Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation","volume":"14","author":"Bartelink","year":"2008","journal-title":"Biol Blood Marrow Transplant."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"E36","DOI":"10.1188\/06.ONF.E36-E43","article-title":"Pretransplant conditioning in adults and children: dose assurance with intravenous busulfan","volume":"33","author":"Fisher","year":"2006","journal-title":"Oncol Nurs Forum"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1517\/17425250903107764","article-title":"Busulfan in hematopoietic stem cell transplant setting","volume":"5","author":"McCune","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003088-200039020-00005","article-title":"Plasma concentration monitoring of busulfan: does it improve clinical outcome?","volume":"39","author":"McCune","year":"2000","journal-title":"Clin Pharmacokinet."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1515\/almed-2022-0016","article-title":"Rapid and accurate method for quantifying busulfan in plasma samples by isocratic liquid chromatography-tandem mass spectrometry (LC-MS\/MS)","volume":"3","author":"Villena-Ortiz","year":"2022","journal-title":"Adv Lab Med\/Avances en Medicina de Laboratorio"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/chromsci\/bmaa093","article-title":"Stability-indicating method development and validation for busulfan drug substance by gas chromatography-flame ionization detector","volume":"59","author":"Khan","year":"2021","journal-title":"J Chromatogr Sci"},{"key":"R9-20250603","article-title":"Simultaneously measure the concentrations of busulfan and phenytoin in human plasma using an HPLC-MS\/MS method: application to the TDM for children underwent hematological stem cell transplantation","author":"Sun","year":"2022","journal-title":"Acta Chromatographica"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-1-4939-3252-8_9","article-title":"A simple liquid chromatography tandem mass spectrometry method for quantitation of plasma Busulfan","volume":"1383","author":"Deng","year":"2016","journal-title":"Methods Mol Biol."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"e4898","DOI":"10.1002\/bmc.4898","article-title":"A rapid HPLC-MS\/MS method for determining busulfan in hemolytic samples from children with hematopoietic stem cell transplantation","volume":"34","author":"Jinjie","year":"2020","journal-title":"Biomed Chromatogr BMC"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"8913","DOI":"10.1038\/s41598-020-65919-9","article-title":"UPLC-Tandem mass spectrometry for quantification of Busulfan in human plasma: application to therapeutic drug monitoring","volume":"10","author":"Matar","year":"2020","journal-title":"Sci Rep."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3343\/alm.2014.34.1.7","article-title":"Quantification of human plasma-busulfan concentration by liquid chromatography-tandem mass spectrometry","volume":"34","author":"Moon","year":"2014","journal-title":"Ann Lab Med."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jpba.2015.12.024","article-title":"LC-MS\/MS method development for quantification of busulfan in human plasma and its application in pharmacokinetic study","volume":"120","author":"Nadella","year":"2016","journal-title":"J Pharm Biomed Anal."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"121711","DOI":"10.1016\/j.jchromb.2019.121711","article-title":"Measurement of the DNA alkylating agents busulfan and melphalan in human plasma by mass spectrometry","volume":"1125","author":"Schofield","year":"2019","journal-title":"J Chromatogr B"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/978-1-60761-459-3_12","article-title":"Quantification of Busulfan in plasma using liquid chromatography electrospray tandem mass spectrometry (HPLC-ESI-MS\/MS)","volume":"603","author":"Snyder","year":"2010","journal-title":"Methods Mol Biol."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.cca.2018.01.020","article-title":"A rapid and simple LC-MS\/MS method for personalized busulfan dosing in pediatric patients undergoing hematopoietic stem cell transplantation (HSCT)","volume":"479","author":"Xiao","year":"2018","journal-title":"Clinica Chim Acta"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/01.ftd.0000443060.22620.cd","article-title":"Development and validation of a liquid chromatography-tandem mass spectrometry assay to quantify plasma busulfan","volume":"36","author":"French","year":"2014","journal-title":"Ther Drug Monit."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jchromb.2017.04.025","article-title":"Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LC-MS\/MS for exposure monitoring in hematopoietic cell transplantation conditioning","volume":"1055-1056","author":"Punt","year":"2017","journal-title":"J Chromatogr B"},{"key":"R20-20250603","first-page":"84","article-title":"Therapeutic drug monitoring of Busulfan for the management of pediatric patients: cross-validation of methods and long-term performance [published correction appears in Ther Drug Monit. 2018 Apr;40(2):284]","volume":"40","author":"Choong","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s13318-020-00660-2","article-title":"Comparison of two analytical methods for Busulfan therapeutic drug monitoring","volume":"46","author":"De Gregori","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/j.0006-341X.2002.01020.x","article-title":"Overall concordance correlation coefficient for evaluating agreement among multiple observers","volume":"58","author":"Barnhart","year":"2002","journal-title":"Biometrics"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.theriogenology.2010.01.003","article-title":"Method agreement analysis: a review of correct methodology","volume":"73","author":"Watson","year":"2010","journal-title":"Theriogenology"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"141","DOI":"10.11613\/BM.2015.015","article-title":"Understanding Bland Altman analysis","volume":"25","author":"Giavarina","year":"2015","journal-title":"Biochem Med (Zagreb)"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/(SICI)1097-0231(19990630)13:12<1175::AID-RCM639>3.0.CO;2-0","article-title":"The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds","volume":"13","author":"Bonfiglio","year":"1999","journal-title":"Rapid Commun Mass Spectrom."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1002\/rcm.2629","article-title":"Identification and reduction of ion suppression effects on pharmacokinetic parameters by polyethylene glycol 400","volume":"20","author":"Weaver","year":"2006","journal-title":"Rapid Commun Mass Spectrom."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:14:05Z","timestamp":1748970845000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001130","relation":{},"ISSN":["0163-4356"],"issn-type":[{"type":"print","value":"0163-4356"}],"subject":[],"published":{"date-parts":[[2023,9,7]]},"assertion":[{"value":"2023-04-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}